The DOI matches its Crossref record.
Advanced Hepatocellular Carcinoma: Early Evaluation of Response to Bevacizumab Therapy at Dynamic Contrast-enhanced US with Quantification—Preliminary Results
Abstract
PURPOSE: To investigate whether there is any correlation between standard efficacy endpoints-specifically, tumor response, progression-free survival, and overall survival-and tumor perfusion parameters measured by using dynamic contrast material-enhanced ultrasonography (US) in patients with advanced hepatocellular carcinoma (HCC) treated with bevacizumab. MATERIALS AND METHODS: The institutional review board approved the study, and all patients provided written informed consent before their enrollment. Between June 3, 2005, and September 28, 2007, 42 patients (33 men, nine women; median age, 62 years; age range, 23-84 years) participated in this phase II study of single-agent bevacizumab treatment. Tumor response (based on RECIST [response evaluation criteria in solid tumors]) at 2 months was assessed in 37 patients, and progression-free survival and overall survival were assessed in all 42 patients. Dynamic contrast-enhanced US (ie, dynamic US) was performed before treatment (day 0); on days 3, 7, 14, and 60 after treatment; and every 2 months thereafter. Tumor perfusion parameters were estimated quantitatively from contrast material uptake curves constructed from raw linear data. The changes in dynamic US functional parameters between day 0 and the later time points were compared between treatment responders and nonresponders by using nonparametric tests. Given multiple comparisons, P < .001 indicated significance. RESULTS: The percentage decrease in several dynamic US parameters between day 0 and day 3 showed trends toward correlation with (a) tumor response in terms of total area under the time-intensity curve (AUC) (P = .02), AUC during wash in (P = .04), AUC during washout (P = .02), and time to peak intensity (P = .03); (b) progression-free survival in terms of time to peak intensity (P = .028); and (c) overall survival in terms of AUC (P = .002) and AUC during washout (P = .003). CONCLUSION: Dynamic US can be used to quantify dynamic changes in tumor vascularity as early as 3 days after bevacizumab administration in patients with HCC. These early changes in tumor perfusion may be predictive of tumor response at 2 months, progression-free survival, and overall survival, and they may be potential surrogate measures of the effectiveness of antiangiogenic therapy in patients with HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Imaging biomarker roadmap for cancer studies
O'Connor, J. P. B., Aboagye, E. O., Adams, J. E., Aerts, H. J. W. L., Barrington, S. F., Beer, A. J., Boellaard, R., Bohndiek, S. E., Brady, M., Brown, G., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.162 · Cited by 1,091
Self-citationSidhu, P., Cantisani, V., Dietrich, C., Gilja, O., Saftoiu, A., Bartels, E., Bertolotto, M., Calliada, F., Clevert, D.-A., Cosgrove, D., et al. (2018) · Ultraschall in der Medizin - European Journal of Ultrasound · doi:10.1055/a-0586-1107 · Cited by 1,086
Self-citationPiscaglia, F., Nolsøe, C., Dietrich, C., Cosgrove, D., Gilja, O., Bachmann Nielsen, M., Albrecht, T., Barozzi, L., Bertolotto, M., Catalano, O., et al. (2011) · Ultraschall in der Medizin - European Journal of Ultrasound · doi:10.1055/s-0031-1281676 · Cited by 1,082
Self-citationClaudon, M., Dietrich, C. F., Choi, B. I., Cosgrove, D. O., Kudo, M., Nolsøe, C. P., Piscaglia, F., Wilson, S. R., Barr, R. G., Chammas, M. C., et al. (2013) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2012.09.002 · Cited by 971
Self-citationClaudon, M., Dietrich, C., Choi, B., Cosgrove, D., Kudo, M., Nolsøe, C., Piscaglia, F., Wilson, S., Barr, R., Chammas, M., et al. (2012) · Ultraschall in der Medizin - European Journal of Ultrasound · doi:10.1055/s-0032-1325499 · Cited by 550
Self-citation
Metadata
- Authors
- Lassau, N., Koscielny, S., Chami, L., Chebil, M., Benatsou, B., Roche, A., Ducreux, M., Malka, D., & Boige, V.
- Venue
- Radiology
- Published
- 2011-01
- Volume
- 258
- Issue
- 1
- Pages
- 291-300
- ISSN
- 0033-8419 (ISSN-L)
- 1527-1315
- OpenAlex
- W2103058588
- Cited by
- 220
- References
- 0
- FWCI
- 15.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advanced Hepatocellular Carcinoma: Early Evaluation of Response to Bevacizumab Therapy at Dynamic Contrast-enhanced US with Quantification—Preliminary Results. https://app.cochat.ai/papers/10.1148/radiol.10091870
- The paper
- Lassau, N., Koscielny, S., Chami, L., Chebil, M., Benatsou, B., Roche, A., Ducreux, M., Malka, D., & Boige, V. (2011). Advanced Hepatocellular Carcinoma: Early Evaluation of Response to Bevacizumab Therapy at Dynamic Contrast-enhanced US with Quantification—Preliminary Results. Radiology. https://doi.org/10.1148/radiol.10091870
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.